Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Beckman Coulter
So what: Citing sources close to the matter, The Wall Street Journal said Beckman could fetch as much as $5 billion in sale, representing a 25% premium to its closing market cap value on Thursday. The news comes amid heavy consolidation in the medical device sector, with the likes of General Electric
Now what: I'd keep my distance from Beckman's shares at this point. The company has hired Goldman Sachs
Interested in more info on Beckman? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, and Motley Fool Options has recommended a diagonal call position on it. The Fool owns shares of Johnson & Johnson and Abbott. Try any of our Foolish newsletter services free for 30 days.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.